WALDENSTROM MACROGLOBULINEMIA

This study compares three drug combinations for people with untreated Waldenstrom's macroglobulinemia, a rare blood cancer. About 92 participants will receive either ibrutinib plus rituximab, zanubrutinib alone, or venetoclax plus rituximab. The goal is to see which approach lead…

This study tests an oral drug called AS-1763 in adults with chronic lymphocytic leukemia, small lymphocytic lymphoma, or other B-cell non-Hodgkin lymphomas who have already tried at least two prior treatments. The main goals are to find the safest dose and see how well the drug c…

This study tests whether a time-limited combination of three drugs (pirtobrutinib, venetoclax, and rituximab) can effectively control Waldenström's macroglobulinemia, a rare blood cancer, in people who have not yet received treatment. About 40 participants will receive the drug c…

This study tests a combination of three drugs (zanubrutinib, bendamustine, and rituximab) in people with Waldenström macroglobulinemia who have not yet received treatment. The goal is to see how many patients achieve a very good partial response or better. About 56 participants w…

This study offers continued access to the drug ibrutinib for up to 700 people with certain blood cancers (like CLL, lymphoma, and Waldenstrom macroglobulinemia) who are already taking it and benefiting. Researchers will track side effects and how the disease changes over time. Th…

This early-stage study tests an experimental oral drug, LP-168, in about 60 people with certain blood cancers (like CLL, lymphoma) that have returned or not responded to prior treatments. The main goals are to find the safest dose and understand how the drug works in the body. Re…

This study tests a drug called venetoclax in about 14 Japanese adults whose Waldenström macroglobulinemia (a rare blood cancer) has returned or not responded to prior treatment. Participants take venetoclax pills daily, with doses slowly increased to a target level. The goal is t…

This study tests a new drug combination (venetoclax plus rituximab) for people newly diagnosed with Waldenström's macroglobulinemia, a rare blood cancer. The goal is to see if this chemotherapy-free approach can achieve deep remissions after a fixed 12-month treatment period, avo…

This early-phase trial tests a new drug called SGR-1505 in about 98 adults with various B-cell blood cancers (like lymphoma and leukemia). The main goals are to find the safest dose and understand side effects. Participants must have measurable disease and be well enough for dail…

This early-phase study tests a new treatment called SynKIR-310 for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior therapies. The treatment uses a patient's own immune cells, modified to target and attack cancer cells. The main go…

This study looks at how often high blood pressure happens in people with certain blood cancers (like CLL or lymphoma) who are taking a type of targeted drug called a BTK inhibitor. The goal is to see if carefully managing that high blood pressure can reduce the risk of serious he…

This study tests a drug called epcoritamab in 20 people with Waldenstrom Macroglobulinemia, a rare blood cancer, who have already had treatment. The drug is a type of antibody that helps the immune system attack cancer cells. The main goal is to see how many patients respond to t…

This study looks at genetic changes in people with early-stage blood cancers or conditions that may lead to cancer. Researchers will analyze blood, bone marrow, or cheek cell samples from up to 10,000 participants to find DNA errors linked to cancer risk and progression. The goal…

This study is creating a national registry of 1,000 people in Spain diagnosed with Waldenström macroglobulinemia or a related condition (IgM-MGUS) over the past 30 years. Researchers will review medical records to understand patient characteristics, treatments, and outcomes. The …

This study follows up to 1,000 adults with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), Waldenstrom macroglobulinemia, or related conditions to learn how these diseases progress over time. Participants receive no treatment as part of the study; instead, t…

This study observes 111 people with Waldenström macroglobulinemia (a rare blood cancer) who are taking the drug zanubrutinib. Researchers want to see how well the drug controls the cancer and what side effects occur, especially in patients with specific genetic mutations and from…

This study is for people with Waldenström Macroglobulinemia, a rare blood cancer. Researchers want to see if detecting tumor DNA in the blood after 6 months of treatment can predict whether the cancer will come back within 3 years. About 90 participants will provide blood samples…